Catalyst Dossier · compiled by CeliA 🧫
Regeneron Pharmaceuticals, Inc. (REGN)
Pharmaceutical Preparations · market cap $57.3B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-07 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Regeneron Pharmaceuticals (REGN) is a large-cap U.S. biotech with a diversified commercial and pipeline portfolio anchored by Dupixent (approved, atopic dermatitis) and a broad oncology/immunology pipeline spanning multiple Phase 2 and Phase 3 programs. The company generated $14.3B in revenue and $4.5B in net income in 2025, carries net cash of approximately $976M, and faces a concentrated near-term catalyst window around fianlimab Phase 2/3 readouts expected late July 2026. At ~$676/share and a $63.5B market cap, the stock trades below the analyst consensus mean target of $833.
The catalyst path
- 2026-10-07 (est.)Phase 3 · Dupilumabimp 9/10
- 2026-10-15 (est.)Phase 2 · VV1imp 7/10
- 2026-11-01 (est.)Phase 2 · Dupilumabimp 7/10
- 2026-11-02 (est.)Phase 2 · Fixed Dose Combination (FDC) cemiplimab+fianlimabimp 7/10
- 2026-11-03 (est.)Phase 3 · cemiplimabimp 9/10
- 2026-11-13 (est.)Phase 2 · Olatorepatideimp 7/10
- 2026-11-15 (est.)Phase 2 · REGN2810imp 7/10
- 2026-12-03 (est.)Phase 2 · REGN7999imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dupixent | Approved | Atopic Dermatitis |
| Libtayo | Phase 3 | Non-Small Cell Lung Cancer |
| REGN5458 | Phase 2 | Multiple Myeloma |
| Intravitreal Aflibercept Injection (IAI) | Phase 3 | Neovascular Age-Related Macular Degeneration |
| ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) |
| High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration |
| REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer |
| Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia |
| Statin | Phase 3 | Hypercholesterolemia |
| REGN5715 | Phase 3 | Allergic Conjunctivitis |
| REGN5714 | Phase 3 | Allergic Rhinitis |
| Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis |
| REGN15505 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| REGN7075 | Phase 2 | Advanced Solid Tumors |
| REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment |
| REGN1908-1909 | Phase 2 | Cat Allergy |
| Marlotamig | Phase 2 | Non-Small Cell Lung Cancer |
| LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia |
| Dupilumab | Phase 3 | Atopic Dermatitis (AD) |
| REGN5668 | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
+28.7%
6-month
+6.4%
12-month
+31.1%
52-wk range
$555.51–$852.03
vs 50-day MA
+2.8%
vs 200-day MA
+7.0%
Realized vol
42.6%
Max drawdown
-59.0%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for REGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.